Johnson & Johnson Medical Technology is partnering with Changyi Da to layout a forward-looking intracranial intervention solution.

Johnson Medical Technology and domestic medical innovation company Changyida have signed an upgraded strategic cooperation agreement. The global research and development team of Johnson Medical Technology's Neuro Interventional Business Unit will lead the collaboration, integrating their respective technological and professional strengths in the field of neuro intervention to accelerate the research and implementation of cutting-edge intracranial intervention solutions. Previously, the innovative product they jointly launched, the Strong Ease Blood Flow-Directed Mesh Stent, was launched in 2025.